First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2011-08-11 10:45:12Open Document File Size: 155,29 KBShare Result on FacebookCityBrussels / /CompanyCelgene Corporation / European Biopharmaceutical Enterprises / /ContinentEurope / / /IndustryTermhealthcare innovation delivering / biopharmaceutical / biotechnology / pharmaceutical industry / biotechnology products / manufacturing / biotechnology arm / biopharmaceutical industry / medicinal products / /MedicalConditionrare and debilitating diseases / rare diseases / metabolic diseases / rare disease / musculoskeletal disorders / certain cancers / individual rare diseases / diseases / /MedicalTreatmentinnovative therapies / /Organizationoffice of Health Economics / Task Force / EuropaBio’s Joint Rare Diseases and Orphan Medicinal Products Task Force / European Association for Bioindustries / Joint Task Force / EuropaBio / European Union / EBE-EuropaBio Joint Task Force / Joint Task Force on Rare Diseases & Orphan Medicinal Products / /PersonKevin Loth / Erik Tambuyzer / Emmanuel Chantelot / / /PositionExecutive Director / Director / Chair / Joanna Dupont-Inglis Communications Manager / Director / External Relations / Europe / /ProgrammingLanguageEC / /PublishedMediumHealth Economics / /Technologybiotechnology / GSM / /SocialTag |